AXIM® Biotechnologies files patent for ELISA-based COVID-19 diagnostic test

AXIM® Biotechnologies files patent application for ELISA based diagnostic test for COVID-19

AXIM® Biotechnologies, Inc., an international healthcare solutions company announced the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based diagnostic test for the detection of SARS‐CoV-2 neutralizing antibodies. This application marks AXIM’s fourth COVID-19 neutralizing antibody-focused patent application (Source- globenewswire)

Fermenta Biotech develops enzymatic synthesis of Molnupiravir – a COVID 19 therapeutic drug

Fermenta Biotech Limited (FBL) files a patent application for novel biocatalytic technology of manufacturing Molnupiravir. This patented enzymatic route of synthesis possesses the technological advantage of being efficient and environment-friendly, with higher yields and lower solvent use as compared to existing reported manufacturing processes. (Source- theweek)

Halberd Corporation files a PCT application for treating and curing Covid-19 infection utilizing a laser

Halberd Corporation files an international Patent Cooperation Treaty (PCT) application for treating and curing Covid-19 infection by exposing the target antigens to laser energy.  Halberd holds exclusive worldwide license to this technology. (Source –  finance.yahoo)

AzurRx BioPharma and First Wave Bio files a patent application for niclosamide that treats COVID-19 GI diseases

AzurRx BioPharma and  First Wave Bio announces allowance of a patent application that covers use of niclosamide as a treatment for COVID-19-associated GI diseases.  The claims of the patent application relate to a method for treating a digestive symptom in a subject diagnosed as having a COVID-19 viral infection by administering an effective amount of niclosamide to decrease viral RNA load relative to a baseline. (Source-  globenewswire)

MGC Pharmaceuticals files a patent application for CimetrA that can treat COVID-19

MGC  Pharmaceuticals’s patent application for CimetrA  is designed to treat multiple ailments including COVID-19. The patent application is filed in Slovenian Intellectual Property Office (SIPO) and is expected to be issued within the next 12 months. (Source- proactiveinvestors)

Therapeutica Borealis receives a patent for coronavirus drug containing ivermectin and hydroxychloroquine

Therapeutica Borealis, a Turku pharmaceutical company obtained a US patent for coronavirus drug. The nasal spray contains hydroxychloroquine among other ingredients. This drug will also help, especially in situations where vaccine coverage threatens to remain too low for livestock immunity, says Vaananen one of the three inventors and founders of Therapeutica Borealis. (Source- nord.news)

RedHill files patent applications for opaganib and RHB-107 in COVID-19

RedHill Biopharma’s patent applications covering opaganib and RHB-107 (upamostat) reveal methods for the treatment of COVID-19. The patent protection extends until at least 2041. (Source- seekingalpha)

Sunshine Biopharma files a non-provisional patent application for its COVID -19 treatment

Sunshine Biopharma Inc. annonunces that it has filed a nonprovisional patent application in the form of a PCT in the United States for its COVID-19 treatment. In addition to the original subject matter disclosed in provisional patent application pertaining to inhibitors of the main coronavirus protease, Mpro, the PCT application contains data and extends coverage to include the papain-like coronavirus protease, PLpro. (Source- globenewswire)